- Home
- WDH vs CRBP Comparison
WDH vs CRBP Comparison
Compare WDH & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDH
- CRBP
- Stock Information
- Founded
- WDH 2016
- CRBP 2009
- Country
- WDH China
- CRBP United States
- Employees
- WDH N/A
- CRBP N/A
- Industry
- WDH Specialty Insurers
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- WDH Finance
- CRBP Health Care
- Exchange
- WDH Nasdaq
- CRBP Nasdaq
- Market Cap
- WDH 420.6M
- CRBP 594.7M
- IPO Year
- WDH 2021
- CRBP N/A
- Fundamental
- Price
- WDH $1.10
- CRBP $50.04
- Analyst Decision
- WDH Strong Buy
- CRBP Strong Buy
- Analyst Count
- WDH 1
- CRBP 5
- Target Price
- WDH $2.80
- CRBP $76.20
- AVG Volume (30 Days)
- WDH 65.9K
- CRBP 261.5K
- Earning Date
- WDH 09-04-2024
- CRBP 08-06-2024
- Dividend Yield
- WDH 4.73%
- CRBP N/A
- EPS Growth
- WDH N/A
- CRBP N/A
- EPS
- WDH 0.10
- CRBP N/A
- Revenue
- WDH $375,221,621.00
- CRBP N/A
- Revenue This Year
- WDH N/A
- CRBP N/A
- Revenue Next Year
- WDH $11.32
- CRBP N/A
- P/E Ratio
- WDH $11.44
- CRBP N/A
- Revenue Growth
- WDH N/A
- CRBP N/A
- 52 Week Low
- WDH $0.94
- CRBP $3.03
- 52 Week High
- WDH $1.53
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- WDH 58.47
- CRBP 40.84
- Support Level
- WDH $1.01
- CRBP $54.23
- Resistance Level
- WDH $1.14
- CRBP $61.72
- Average True Range (ATR)
- WDH 0.04
- CRBP 4.16
- MACD
- WDH 0.01
- CRBP -0.95
- Stochastic Oscillator
- WDH 69.23
- CRBP 11.83
About WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. It is a third-party insurance platform in China in terms of life and health insurance.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.